Regulus Therapeutics (NASDAQ:RGLS) Shares Cross Above 200-Day Moving Average of $0.87

Regulus Therapeutics Inc (NASDAQ:RGLS) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.87 and traded as high as $0.94. Regulus Therapeutics shares last traded at $0.80, with a volume of 5,500 shares changing hands.

A number of analysts have issued reports on RGLS shares. HC Wainwright started coverage on Regulus Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $2.00 target price on the stock. Wedbush reaffirmed a “hold” rating and issued a $1.00 target price on shares of Regulus Therapeutics in a report on Thursday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, August 13th. Finally, Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Wednesday, November 20th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $1.31.

The stock has a market cap of $17.37 million, a price-to-earnings ratio of -0.14 and a beta of 1.55. The stock has a fifty day simple moving average of $0.68 and a 200-day simple moving average of $0.87.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.26). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative return on equity of 163,378.48% and a negative net margin of 325.85%. Sell-side analysts predict that Regulus Therapeutics Inc will post -0.86 earnings per share for the current year.

Large investors have recently made changes to their positions in the company. NEA Management Company LLC lifted its position in shares of Regulus Therapeutics by 124.1% during the 2nd quarter. NEA Management Company LLC now owns 2,052,455 shares of the biopharmaceutical company’s stock worth $2,566,000 after buying an additional 1,136,704 shares during the period. EcoR1 Capital LLC bought a new position in shares of Regulus Therapeutics during the 2nd quarter worth approximately $1,389,000. Samsara BioCapital LLC bought a new position in shares of Regulus Therapeutics during the 2nd quarter worth approximately $1,131,000. Finally, CVI Holdings LLC bought a new position in shares of Regulus Therapeutics during the 2nd quarter worth approximately $568,000. 36.76% of the stock is currently owned by institutional investors.

About Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Article: High-Yield Dividend Stocks

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.